secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0001104659-25-088021
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports $2.1M net product revenue from AVMAPKI FAKZYNJA launch in first 6 weeks
--------------------------------------------------------------------------------

- AVMAPKI FAKZYNJA co-pack approved May 8, 2025 for KRAS-mutant recurrent LGSOC; $2.1M net revenue in first six weeks.
- RAMP 201 trial showed 44% ORR and median DoR 3.3-31.1 months for approved combination.
- RAMP 205 dose level 1 in 1L metastatic pancreatic cancer achieved 83% confirmed ORR (10/12).
- VS-7375 (KRAS G12D inhibitor) Phase 1/2a trial dosed first patient in U.S.; Fast Track designation granted.
- RAMP 301 confirmatory trial enrollment on track for completion by end of 2025; IDMC recommendation expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925088021/0001104659-25-088021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925088021/tm2525447d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-088021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer